scholarly journals Response to Letter Regarding Article, “Mortality and Readmission of Patients With Heart Failure, Atrial Fibrillation, or Coronary Artery Disease Undergoing Noncardiac Surgery: An Analysis of 38 047 Patients”

Circulation ◽  
2012 ◽  
Vol 125 (6) ◽  
Author(s):  
Sean van Diepen ◽  
Justin A. Ezekowitz ◽  
Jeffrey A. Bakal ◽  
Finlay A. McAlister
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Noncardiac Surgery ◽  
Patients With Heart Failure ◽  
Artery Disease

The Role of Antithrombotic Therapy in Heart Failure

2020 ◽  
Vol 26 (23) ◽  
pp. 2735-2761
Author(s):  
Christina Chrysohoou ◽  
Nikolaos Magkas ◽  
Christos-Konstantinos Antoniou ◽  
Panagiota Manolakou ◽  
Aggeliki Laina ◽  
...  
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Antithrombotic Therapy ◽  
Left Ventricular Ejection ◽  
Heart Failure Patients ◽  
Patients With Heart Failure ◽  
Artery Disease

: Heart failure is a major contributor to global morbidity and mortality burden affecting approximately 1-2% of adults in developed countries, mounting to over 10% in individuals aged >70 years old. Heart failure is characterized by a prothrombotic state and increased rates of stroke and thromboembolism have been reported in heart failure patients compared with the general population. However, the impact of antithrombotic therapy on heart failure remains controversial. Administration of antiplatelet or anticoagulant therapy is the obvious (and well-established) choice in heart failure patients with cardiovascular comorbidity that necessitates their use, such as coronary artery disease or atrial fibrillation. In contrast, antithrombotic therapy has not demonstrated any clear benefit when administered for heart failure per se, i.e. with heart failure being the sole indication. Randomized studies have reported decreased stroke rates with warfarin use in patients with heart failure with reduced left ventricular ejection fraction, but at the expense of excessive bleeding. Non-vitamin K oral anticoagulants have shown a better safety profile in heart failure patients with atrial fibrillation compared with warfarin, however, current evidence about their role in heart failure with sinus rhythm is inconclusive and further research is needed. In the present review, we discuss the role of antithrombotic therapy in heart failure (beyond coronary artery disease), aiming to summarize evidence regarding the thrombotic risk and the role of antiplatelet and anticoagulant agents in patients with heart failure.

scholarly journals Clinical and functional characteristics of hospitalized patients with heart failure in the routine clinical practice

2021 ◽  
Vol 27 (6) ◽  
pp. 41-46
Author(s):  
V. I. Tseluyko ◽  
A. O. Lukyanenko ◽  
L. M. Yakovleva
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Coronary Artery Disease ◽  
Clinical Practice ◽  
Coronary Artery ◽  
Left Ventricle Ejection Fraction ◽  
Routine Clinical Practice ◽  
Functional Characteristics ◽  
Patients With Heart Failure ◽  
Artery Disease

The aim – to provide сlinical and functional characteristics of patients with heart failure (HF) admitted to the cardiologic clinic Materials and methods. We studied 150 in-patient cards of the patients who were consecutively admitted to City Clinical Hospital N 8 between August 2018 and September 2019. 124 (80.6 %) patients who had the diagnosis of HF were selected for the future analysis.Results and discussion. Among the examined HF patients, 89 (71.8 %) had HF stage ІІА,18 (14.5 %) had stage IIB and 17 (13.7 %) had stage I. 23 (18,5 %) of patients had left ventricle ejection fraction (LVEF) below 40 %, 101 (81.5 %) had preserved LVEF. 73 (58.9 %) of examined patients with HF were male, 51 (41.1 %) were female. Women were elder then men and were more likely to have stage II arterial hypertension (AH) while men were more likely to have stage 3 AH. Most females had HF with preserved LVEF.Conclusions. Most patients with HF have preserved LVEF which can be the result of HF hyperdiagnistics in the situation of missing NT-proBNP assessment. In the group of patients with preserved LVEF HF 19.8 % of patients have EF of 40–49 % while 20.8 % have LVEF over 62 %. The most common comorbidity in patients with preserved LVEF HF was AH (88.1 %), coronary artery disease (77.2 %), atrial fibrillation (29.4 %).

Sign in / Sign up

Export Citation Format

Share Document